Board Disclosures

The leadership of the Bladder Cancer has disclosed the following information in keeping with the journal's disclosure policy.

Seth P. Lerner, MD, Editor-in-Chief
Advisory Board (with honoraria): BioCancell, miR Scientific, QED Therapeutics, UroGen
Clinical Trials: Endo, FKD, JBL (SWOG), Roche/Genentech (SWOG), Viventia
Consultant (with honoraria): BioCancell, UroGen, Vaxiion
Honoraria: BioCancell, miR Scientific, QED Therapeutics, UroGen, MSD Korea (speaker honoraria)
Patent Pending: TCGA subtypes single patient classifier (the Broad Institute)
Other: IOS Press (editorial responsibilities, compensated)

Dan Theodorescu, MD, PhD, Editor-in-Chief
Consultant: Machavert, Merck, Urogen
Honoraria: Machavert, Merck, Urogen
Licenses/Patents: University of Colorado
Research Support: Medivation/Astellas
Stockholder in: Aurora Oncology, PrecisionProfile
Other: IOS Press (editorial responsibilities, compensated)

Cora N. Sternberg, MD, Associate Editor
Renal
Honoraria: Pfizer, IPSEN
Consultant: Eisai, Pfizer, IPSEN, BMS, Roche, Bayer, MSD, Novartis

Bladder
Consultant: Merck, Clovis, BMS, Incyte, AstraZeneca
Honoraria: Lilly
Institutional Funding: Janssen

Prostate
Consultant: Sanofi, Bayer, Pfizer
Honoraria: Clovis, Janssen, AstraZeneca, Sanofi, Astellas
Institutional Funding: Roche-Genentech, Bayer, Sanofi , Janssen, Medivation, Exelixis, Sanofi Genzyme

Piyush K. Agarwal, MD, Associate Editor
Nothing to Disclose

Edward M. Messing, MD, Associate Editor
Nothing to Disclose

Mark S. Soloway, MD, Associate Editor
Nothing to Disclose

Last updated: 31 October 2018